Abstract
Background Understanding the kinetics and longevity of antibody responses to SARS-CoV-2 is critical to informing strategies toward reducing Coronavirus disease 2019 (COVID-19) reinfections, and improving vaccination and therapy approaches.
Methods We evaluated antibody titers against SARS-CoV-2 nucleocapsid (N), spike (S), and receptor binding domain (RBD) of spike in 98 convalescent participants who experienced asymptomatic, mild, moderate or severe COVID-19 disease and in 17 non-vaccinated, non-infected controls, using four different antibody assays. Participants were sampled longitudinally at 1, 3, 6, and 12 months post-SARS-CoV-2 positive PCR test.
Findings Increasing acute COVID-19 disease severity correlated with higher anti-N and anti-RBD antibody titers throughout 12 months post-infection. Anti-N and anti-RBD titers declined over time in all participants, with the exception of increased anti-RBD titers post-vaccination, and the decay rates were faster in hospitalized compared to non-hospitalized participants. <50% of participants retained anti-N titers above control levels at 12 months, with non-hospitalized participants falling below control levels sooner. Nearly all hospitalized and non-hospitalized participants maintained anti-RBD titers above controls for up to 12 months, suggesting longevity of protection against severe reinfections. Nonetheless, by 6 months, few participants retained >50% of their 1-month anti-N or anti-RBD titers. Vaccine-induced increases in anti-RBD titers were greater in non-hospitalized relative to hospitalized participants. Early convalescent antibody titers correlated with age, but no association was observed between Post-Acute Sequelae of SARS-CoV-2 infection (PASC) status or acute steroid treatment and convalescent antibody titers.
Interpretation Hospitalized participants developed higher anti-SARS-CoV-2 antibody titers relative to non-hospitalized participants, a difference that persisted throughout 12 months, despite the faster decline in titers in hospitalized participants. In both groups, while anti-N titers fell below control levels for at least half of the participants, anti-RBD titers remained above control levels for almost all participants over 12 months, demonstrating generation of long-lived antibody responses known to correlate with protection from severe disease across COVID-19 severities. Overall, our findings contribute to the evolving understanding of COVID-19 antibody dynamics.
Funding Austin Public Health, NIAAA, Babson Diagnostics, Dell Medical School Startup.
Competing Interest Statement
Nadia Siles: Recipient of National Consortium for Graduate Degrees for Minorities in Engineering and Science (GEM) Fellowship Maisey Schuler: Nothing to disclose Cole Maguire: Recipient of NIDA T32 Training Grant 5T32DA018926-18 for graduate student stipend and travel support for scientific conferences from the European Committee for Treatment and Research in Multiple Sclerosis Dzifa Amengor: Nothing to disclose Annalee Nguyen: Nothing to disclose Rebecca Wilen: Nothing to disclose Jacob Rogers: Nothing to disclose Sam Bazzi: Recipient of NIH NIAAA T32AA007471 and Fred Murphy Jones & Homer Lindsey Bruce Endowed Fellowships for graduate student stipend Blaine Caslin: Nothing to disclose Christopher DiPasquale: Vice President of Assay Development of Babson Diagnostics, Inc.; holder of stock/stock options for Babson; salary as employee of Babson Melissa Abigania: Nothing to disclose Eric Olson: Chairman of the Board of Babson Diagnostics, Inc.; holder of stock/stock options for Babson; salary as employee of Babson Todd Triplett: Nothing to disclose Janelle Creaturo: Nothing to disclose Kerin Hurley: Nothing to disclose Justin F. Rousseau: Recipient of NIH National Institute of Allergy and Infectious Diseases (NIAID) funding for another project Stephen M. Strakowski: Recipient of NIH National Institute of Mental Health and Jassen funding for other projects and consulting fees for Sunovion, WebMD, and Meadows Mental Health Policy Institute; holds leadership role with American Brain Coalition and National Network Depression Centers Dennis Wylie: Nothing to disclose Jennifer Maynard: Recipient of grant funding from Welch Foundation, Texas Biologics, NIAID, and National Science Foundation; consulting fees from Sidley on behalf of Amgen and Genentech; and travel support for attending PEGS Protein & Antibody Engineering Summit 2023, Gordon conference on Protein Engineering 2023, and MD Anderson & UT Austin Collaborative Research Summit 2023; license holder for HexaPro (multiple non-exclusive licenses) and 3A3 antibody, specific for prefusion spike; and member of scientific advisory boards of Janux (2019-present) and Releviate (2020-present) Lauren I. R. Ehrlich: Nothing to disclose Esther Melamed: Recipient of research funding from Babson Diagnostics; consulting fees from Horizon, Roche, Summus; honoraria from the National Center for Health Research and American Academy of Physical Medicine and Rehabilitation; and travel support for scientific conferences from the NIH, National Center for Health Research, and American Academy of Physical Medicine and Rehabilitation
Funding Statement
This work was supported by Austin Public Health grant 4700 NI210000003, NIAAA K08 T26-1616-11, NIH/NIAID R01AI104870, research funds from Babson Diagnostics, and institutional Dell Medical School Startup funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Broad of the University of Texas at Austin gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declaration of interests
Nadia Siles: Recipient of National Consortium for Graduate Degrees for Minorities in Engineering and Science (GEM) Fellowship
Maisey Schuler: Nothing to disclose
Cole Maguire: Recipient of NIDA T32 Training Grant 5T32DA018926-18 for graduate student stipend and travel support for scientific conferences from the European Committee for Treatment and Research in Multiple Sclerosis
Dzifa Amengor: Nothing to disclose
Annalee Nguyen: Nothing to disclose
Rebecca Wilen: Nothing to disclose
Jacob Rogers: Nothing to disclose
Sam Bazzi: Recipient of NIH NIAAA T32AA007471 and Fred Murphy Jones & Homer Lindsey Bruce Endowed Fellowships for graduate student stipend
Blaine Caslin: Nothing to disclose
Christopher DiPasquale: Vice President of Assay Development of Babson Diagnostics, Inc.; holder of stock/stock options for Babson; salary as employee of Babson
Melissa Abigania: Nothing to disclose
Eric Olson: Chairman of the Board of Babson Diagnostics, Inc.; holder of stock/stock options for Babson; salary as employee of Babson
Todd Triplett: Nothing to disclose
Janelle Creaturo: Nothing to disclose
Kerin Hurley: Nothing to disclose
Justin F. Rousseau: Recipient of NIH National Institute of Allergy and Infectious Diseases (NIAID) funding for another project Stephen M. Strakowski: Recipient of NIH National Institute of Mental Health and Jassen funding for other projects and consulting fees for Sunovion, WebMD, and Meadows Mental Health Policy Institute; holds leadership role with American Brain Coalition and National Network Depression Centers
Dennis Wylie: Nothing to disclose
Jennifer Maynard: Recipient of grant funding from Welch Foundation, Texas Biologics, NIAID, and National Science Foundation; consulting fees from Sidley on behalf of Amgen and Genentech; and travel support for attending PEGS Protein & Antibody Engineering Summit 2023, Gordon conference on Protein Engineering 2023, and MD Anderson & UT Austin Collaborative Research Summit 2023; license holder for HexaPro (multiple non-exclusive licenses) and 3A3 antibody, specific for prefusion spike; and member of scientific advisory boards of Janux (2019 – present) and Releviate (2020-present)
Lauren I. R. Ehrlich: Nothing to disclose
Esther Melamed: Recipient of research funding from Babson Diagnostics; consulting fees from Horizon, Roche, Summus; honoraria from the National Center for Health Research and American Academy of Physical Medicine and Rehabilitation; and travel support for scientific conferences from the NIH, National Center for Health Research, and American Academy of Physical Medicine and Rehabilitation
Data Availability
The anonymized data supporting this publication is available at ImmPort (https://www.immport.org) under study accession SDY2423.
